logo

For the Inventor, By the Inventor

Amsterdam, Netherlands

Abgenomics Cooperatief U.a.


USPTO Granted Patents = 12

% Expired Patents = 58.3



Forward Citations = 89

Loading Chart...
Loading Chart...

6 inventors (with patents filed for the assignee):

goldMedal Rong-Hwa Lin (12 out of 20 patents)

silverMedal Chung Nan Chang (9 out of 10 patents)

bronzeMedal Chiu-Chen Huang (7 out of 12 patents)

4.  Pei-Jiun Chen (7 out of 7 patents)

5.  Chung-Hsiun Wu (3 out of 6 patents)

6.  Pei-Ling Hsu (3 out of 4 patents)

7.  Wu Chung-Hsiun (0 patent)

8.  Lin Rong-Hwa (0 patent)

9.  Hsu Pei-Ling (0 patent)

10.  Ronghwa Lin (0 patent)

11.  Rong-Hwa Lin (0 patent)

12.  Lin Rong-Hwa (0 patent)

13.  Wu Chung-Hsiun (0 patent)

14.  Hsu Pei-Ling (0 patent)


12 patents:

1. 10030075 - Methods of treating with anti-PSGL-1 antibodies (2018-07-24),
2. 9631019 - Methods of treating GVHD and transplant rejection with anti-PSGL-1 antibodies (2017-04-25),
3. 9494574 - T-cell death-inducing epitopes (2016-11-15),
4. 8828397 - Anti-PSGL-1 antibodies and methods of inducing cell death of an activated T cell (2014-09-09),
5. 8663641 - Anti-PSGL-1 antibodies (2014-03-04),
6. 8628775 - Methods of reducing T cell-mediated immune responses with multimeric P-selectin and/or E-selectin compounds (2014-01-14),
7. 8557579 - Screening for modulators of PSGL-1 with respect to T cell or NK cell death (2013-10-15),
8. 8361472 - Anti-PSGL-1 antibodies (2013-01-29),
9. 8298540 - Methods of modulating T cell-mediated immune responses with anti-P-selectin glycoprotein ligand 1 antibodies (2012-10-30),
10. 8287871 - Methods of inducing cell death of an activated T cell with anti-PSGL-1 antibodies (2012-10-16),
11. 7744888 - Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies (2010-06-29),
12. 7604800 - Anti-PSGL-1 antibodies (2009-10-20),
Company Overview
Abgenomics Cooperatief U.a. is a biotechnology organization based in Amsterdam, specializing in the development of innovative therapeutic solutions. The company focuses on advancing research in the fields of immunology and oncology, leveraging cutting-edge technologies to create novel treatments. With a commitment to addressing unmet medical needs, Abgenomics collaborates with various stakeholders in the healthcare ecosystem to enhance patient outcomes and contribute to the evolution of modern medicine.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

12 Patents

#52 in Amsterdam

#542 in Netherlands

#48,163 in the World

Amsterdam, NL
Amsterdam, Netherlands

Abgenomics Cooperatief U.a.

Forward Citations = 89

6 inventors:

goldMedal Rong-Hwa Lin (12 out of 20 patents)

silverMedal Chung Nan Chang (9 out of 10 patents)

bronzeMedal Chiu-Chen Huang (7 out of 12 patents)

4.  Pei-Jiun Chen (7 out of 7 patents)

5.  Chung-Hsiun Wu (3 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Abgenomics Cooperatief U.a.. Retrieved from https://idiyas.com/company/abgenomics-cooperatief-u-a

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…